(1S,5S)-isopropyl 3-(6-(2-chloro-4-cyanophenylamino)-5-fluoropyrimidin-4-yloxy)-8-azabicyclo[3.2.1]octane-8-carboxylate

ID: ALA4164666

Chembl Id: CHEMBL4164666

PubChem CID: 145963524

Max Phase: Preclinical

Molecular Formula: C22H23ClFN5O3

Molecular Weight: 459.91

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)OC(=O)N1[C@H]2CC[C@H]1CC(Oc1ncnc(Nc3ccc(C#N)cc3Cl)c1F)C2

Standard InChI:  InChI=1S/C22H23ClFN5O3/c1-12(2)31-22(30)29-14-4-5-15(29)9-16(8-14)32-21-19(24)20(26-11-27-21)28-18-6-3-13(10-25)7-17(18)23/h3,6-7,11-12,14-16H,4-5,8-9H2,1-2H3,(H,26,27,28)/t14-,15-/m0/s1

Standard InChI Key:  SMJQLJGGSGVIGM-GJZGRUSLSA-N

Alternative Forms

  1. Parent:

    ALA4164666

    ---

Associated Targets(Human)

GPR119 Tclin Glucose-dependent insulinotropic receptor (4762 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Gpr119 Glucose-dependent insulinotropic receptor (559 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 459.91Molecular Weight (Monoisotopic): 459.1473AlogP: 4.80#Rotatable Bonds: 5
Polar Surface Area: 100.37Molecular Species: NEUTRALHBA: 7HBD: 1
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 10.25CX Basic pKa: 2.59CX LogP: 4.30CX LogD: 4.29
Aromatic Rings: 2Heavy Atoms: 32QED Weighted: 0.68Np Likeness Score: -1.30

References

1. Neelamkavil SF, Stamford AW, Kowalski T, Biswas D, Boyle C, Chackalamannil S, Xia Y, Jayne C, Neustadt B, Hao J, Liu H, Dai X, Baker H, Hawes B, O'Neill K, Tang H, Greenlee WJ..  (2018)  Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes.,  (5): [PMID:29795759] [10.1021/acsmedchemlett.8b00073]

Source